Stay updated on Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial page
- CheckyesterdayChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 from the page's version history.SummaryDifference0.1%

- Check8 days agoChange DetectedUpdated the page revision from v3.4.2 to v3.4.3 in the footer.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedRevision tag updated to v3.4.2 was added and the previous revision notice v3.4.1 along with the government-funding/operating status notice were removed.SummaryDifference0.5%

- Check44 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and updated operation status guidance. Updated the page version from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check51 days agoChange DetectedThe changes include adding a glossary display option, updating the wording of QC-related fields (Last Update Submitted that Met QC Criteria) and capitalization for No FEAR Act Data, and introducing the Revision: v3.4.0 indicator. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check65 days agoChange DetectedThe page revision updated from v3.3.3 to v3.3.4; this is minor metadata with no visible changes to the study’s content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial page.